New developments in the management of Waldenstrom macroglobulinemia

被引：11

作者：

Abeykoon, Jithma P. ^{[1
]}

Yanamandra, Uday ^{[2
]}

Kapoor, Prashant ^{[1
,3
]}

机构：

[1] Mayo Clin, Dept Internal Med, Rochester, MN USA

[2] Army Hosp Res & Referral, Dept Hematol & Stem Cell Transplant, Delhi, India

[3] Mayo Clin, Div Hematol, 200 First St SW, Rochester, MN 55905 USA

来源：

CANCER MANAGEMENT AND RESEARCH | 2017年 / 9卷

关键词：

lymphoplasmacytic lymphoma; indolent lymphoma; MYD88; CXCR4; management; ibrutinib; LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA; COOPERATIVE-ONCOLOGY-GROUP; BRUTON TYROSINE KINASE; LATE-ONSET NEUTROPENIA; VON-WILLEBRAND-FACTOR; END RESULTS DATABASE; PHASE-II TRIAL; ATRIAL-FIBRILLATION; TREATMENT RECOMMENDATIONS; INTERNATIONAL WORKSHOP;

D O I：

10.2147/CMAR.S94059

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Waldenstrom macroglobulinemia (WM) is a rare, immunoglobulin M -associated lymphoplasmacytic lymphoma. With the recent discoveries of CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) and MYD88 mutations, our understanding of the biology of WM has expanded substantially. While WM still remains incurable, the field is rapidly evolving, and a number of promising agents with significant activity in this malignancy are being evaluated currently. In this review, we discuss the new developments that have occurred in WM over the past 15 years, with a focus on the role of ibrutinib, an oral Bruton's tyrosine kinase inhibitor that has recently been approved for WM in the United States, Europe, and Canada.

引用

页码：73 / 83

页数：11

共 91 条

[1] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[2] Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines [J].

Ansell, Stephen M. ;

Kyle, Robert A. ;

Reeder, Craig B. ;

Fonseca, Rafael ;

Mikhael, Joseph R. ;

Morice, William G. ;

Bergsagel, P. Leif ;

Buadi, Francis K. ;

Colgan, Joseph P. ;

Dingli, David ;

Dispenzieri, Angela ;

Greipp, Philip R. ;

Habermann, Thomas M. ;

Hayman, Suzanne R. ;

Inwards, David J. ;

Johnston, Patrick B. ;

Kumar, Shaji K. ;

Lacy, Martha Q. ;

Lust, John A. ;

Markovic, Svetomir N. ;

Micallef, Ivana N. M. ;

Nowakowski, Grzegorz S. ;

Porrata, Luis F. ;

Roy, Vivek ;

Russell, Stephen J. ;

Short, Kristen E. Detweiler ;

Stewart, A. Keith ;

Thompson, Carrie A. ;

Witzig, Thomas E. ;

Zeldenrust, Steven R. ;

Dalton, Robert J. ;

Rajkumar, S. Vincent ;

Gertz, Morie A. .

MAYO CLINIC PROCEEDINGS, 2010, 85 (09) :824-833

[3] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[4] The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia [J].

Cao, Y. ;

Hunter, Z. R. ;

Liu, X. ;

Xu, L. ;

Yang, G. ;

Chen, J. ;

Patterson, C. J. ;

Tsakmaklis, N. ;

Kanan, S. ;

Rodig, S. ;

Castillo, J. J. ;

Treon, S. P. .

LEUKEMIA, 2015, 29 (01) :169-176

[5] The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild-type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells [J].

Cao, Yang ;

Yang, Guang ;

Hunter, Zachary R. ;

Liu, Xia ;

Xu, Lian ;

Chen, Jie ;

Tsakmaklis, Nickolas ;

Hatjiharissi, Evdoxia ;

Kanan, Sandra ;

Davids, Matthew S. ;

Castillo, Jorge J. ;

Treon, Steven P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) :134-138

[6] CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P-directed survival signalling in Waldenstrom macroglobulinaemia cells [J].

Cao, Yang ;

Hunter, Zachary R. ;

Liu, Xia ;

Xu, Lian ;

Yang, Guang ;

Chen, Jie ;

Tsakmaklis, Nickolas ;

Kanan, Sandra ;

Castillo, Jorge J. ;

Treon, Steven P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (05) :701-707

[7] Genomic organization and promoter characterization of human CXCR4 gene [J].

Caruz, A ;

Samsom, M ;

Alonso, JM ;

Alcami, J ;

Baleux, F ;

Virelizier, JL ;

Parmentier, M ;

Arenzana-Seisdedos, F .

FEBS LETTERS, 1998, 426 (02) :271-278

[8] Lower Doses of Bendamustine Are Not Associated with Lower Response Rates in Previously Untreated Patients with Waldenstrom Macroglobulinemia [J].

Castillo, Jorge J. ;

Gustine, Joshua ;

Meid, Kirsten ;

Dubeau, Toni ;

Ghobrial, Irene M. ;

Treon, Steven P. .

BLOOD, 2016, 128 (22)

[9] Idelalisib in Waldenstrom macroglobulinemia: high incidence of hepatotoxicity [J].

Castillo, Jorge J. ;

Gustine, Joshua N. ;

Meid, Kirsten ;

Dubeau, Toni ;

Yang, Guang ;

Xu, Lian ;

Hunter, Zachary R. ;

Treon, Steven P. .

LEUKEMIA & LYMPHOMA, 2017, 58 (04) :1002-1004

[10] Rituximab intolerance in patients with Waldenstrom macroglobulinaemia [J].

Castillo, Jorge J. ;

Kanan, Sandra ;

Meid, Kirsten ;

Manning, Robert ;

Hunter, Zachary R. ;

Treon, Steven P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (04) :645-648

← 1 2 3 4 5 6 7 8 9 10 →